fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Doxycycline hyclate

All products: not a benefit

Vibra-Tabs · DIN 00578452 · 100 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.Discontinued April 4, 2014 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-04-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Vibra-Tabs · DIN 00578452 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2014-04-04 · brand VIBRA-TABS · ATC J01AA02 DOXYCYCLINE · form Tablet · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE HYCLATE) 100 MG · company S wolz zell-hefe gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vibra-Tabs: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00578452)

Source record
DIN 00578452: Vibra-Tabs Raw flags: notABenefit=Y, sec3=Y Item: 081224015; group id 32; item number 0067; lccId None; manufacturer id PFI Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00578452 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6795
Interchangeable products
Apo-Doxy-Tabs · DIN 00874256 · $0.4560 Bio-Doxycycline · DIN 02561115 · $0.4560 Doxycycline Tablets · DIN 02351242 · $0.4560 Jamp Doxycycline Tablets · DIN 02554372 · $0.4560 M-Doxycycline · DIN 02543478 · $0.4560 NRA-Doxycycline · DIN 02558505 · $0.4560 PRZ-Doxycycline · DIN 02536250 · $0.4560 Teva-Doxycycline · DIN 02158574 · $0.4560
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since April 4, 2014 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01AA): coverage varies; not interchangeable

  • Minocycline: general benefit, not a benefit
  • Tetracycline (Tetracyn): general benefit, not a benefit
  • Tigecycline (Tygacil): general benefit
  • Doxycycline (Apprilon): not a benefit
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered

Matched class: 08:12:24 Tetracyclines

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: TIGECYCLINE Some products covered without a code (check the product listing): MINOCYCLINE HCL, TETRACYCLINE 08:12:24 Tetracyclines

MINOCYCLINE HCL

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 50mg, 100mg · Cap

TETRACYCLINE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

TIGECYCLINE

· 1 products · General benefit · strengths: 50mg/Vial · Pd for Inj-5mLVial Pk (Preservative-Free)

DOXYCYCLINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · MR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:24
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-DOXY / APO-DOXY-TABS (doxycycline hyclate) may be indicated for the treatment of: • Pneumonia Single and multilobe pneumonia and bronchopneumonia due to susceptible strains of Streptococcus pneunomiae and other Streptococcus spp., Staphylococcus spp., H. influenzae and Klebsiella pneumoniae. • Other Respiratory Tract Infections Pharyngitis, tonsillitis, sinusitis, otitis media, bronchitis caused by susceptible strains of β- hemolytic Streptococcus, Staphylococcus spp., Streptococcus pneunomiae and H. influenzae. • Genitourinary Tract Infections Pyelonephritis, cystitis, urethritis caused by susceptible strains of Klebsiella spp., Enterobacter aerogenes, E. coli, Enterococcus spp., Staphylococcus spp., Streptococcus spp. and gonococcal urethritis caused by Neisseria gonorrhoeae. In adult patients with urethritis, cervicitis and vaginitis with a positive test for Chlamydia trachomatis and/or Ureaplasma urealyticum, clinical resolution and absence of detectable organisms have only been observed at completion of ORAL therapy with doxycycline. Relapses or reinfection can occur. In these cases, limited data suggest … https://pdf.hres.ca/dpd_pm/00084988.PDF PM date: 2026-06-05 Source product: APO-DOXY-TABS; DIN 00874256; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Vibra-Tabs: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026